NCT05439824进行中（未招募）2 期
A Randomized, Observer-blinded, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Immunogenicity and Safety of a SARS-CoV-2 mRNA Vaccine (SYS6006) in Healthy Participants Aged 18 Years or More
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.2 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2022年6月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
- 试验地点
- 2
- 主要终点
- Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody
研究概览
简要总结
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age at the time of the first dose of vaccine: 18 and above;
- •Axillary body temperature is less than 37.3 degree centigrade on the day of enrollment;
- •Based on the medical history, physical examination and laboratory examination results, the investigator clinically determined the qualified person.
- •Has independent judgment, and participate voluntarily and sign an informed consent form.
排除标准
- •Those who meet any of the following criteria must be excluded from this study:
- •Has a history of SARS or SARS-CoV-2 infection, or close contact with SARS-CoV-2 infected person( nucleic acid test positive), or living abroad within 30 days before screening;
- •Positive for SARS-CoV-2 antibody test;
- •History of allergy to paracetamol or vaccination (such as acute allergic reaction, urticaria, dyspnea, angioedema, or abdominal pain);
- •Has a history of vaccination with SARS-CoV-2 vaccine, or vaccination with other inactivated or recombinant vaccine within 7 days or received live attenuated vaccine within 14 days before the first dose;
- •Has a medical or family history of epilepsy or convulsion, neurological disorders, mental disorders, etc.;
- •Is contraindications for intramuscular injection, such as diagnosed thrombocytopenia, any coagulation disorder or receiving anticoagulant treatment, etc.;
- •Has known or suspected serious disorders judged by the Investigator, including but not limited to respiratory disorders (pulmonary failure, etc.), liver and kidney disorders, cardiovascular disorders (cardiac failure, severe hypertension, etc.), malignant tumors, infections or allergic skin disorders, HIV infection, or in the acute infection or chronic disease activity period (within 3 days before vaccination);
- •Has chronic diseases (such as Down syndrome, sickle cell anemia, neurological disorders and Guillain-Barre syndrome, excluding chronic diseases such as controlled stable diabetes mellitus/hypertension/hyperlipidemia) that are not suitable for this study at the discretion of the Investigator;
- •Has known immunological impairment or immunodeficiency diagnosed by hospital before enrollment, or functional asplenia or splenectomy caused by any condition;
- •For women of childbearing potential: positive pregnancy test before the enrollment, being in pregnant, breastfeeding, or have a pregnancy plan within 1 year; men: whose spouses is of childbearing potential and has a pregnancy plan within 1 year;
- •Is participating or plan to participate in other clinical studies during the study;
- •Has received immune enhancement or immunosuppressive therapy within 3 months (continuous oral or instillation for more than 14 days); or received treatment with whole blood, plasma and immunoglobulin within 1 month;
- •Is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or has other conditions that are not suitable for participating in this clinical trial.
结局指标
主要结局
Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody
时间窗: 14 days after the second dose
Adverse events (AEs), including solicited AEs and unsolicited AEs
时间窗: From the first dose through 30 days following the second dose
AEs associated with the study intervention
时间窗: From the first dose through 30 days following the second dose
次要结局
- Serious adverse events (SAEs)(from the first dose through 12 months after the second dose.)
- Adverse events of special interest (AESIs)(rom the first dose through 12 months after the second dose.)
- Laboratory test related adverse events(4 days following each dose.)
- GMT, GMI and SCR of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody(30, 90, 180 and 360 days after the second dose.)
- Geometric Mean Titer(GMT), Geometric Mean Fold Increase (GMI) and Seroconversion Rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody(from the first dose through 21 days)
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult VolunteersCOVID-19NCT04773067United Biomedical Inc., Asia3,877
招募中
2 期
Study of Stapokibart Injection in Patients With Allergic RhinitisAllergic RhinitisNCT06525597Keymed Biosciences Co.Ltd120
已完成
2 期
A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 VaccineCOVID-19 PandemicNCT05652543Sinocelltech Ltd.518
进行中（未招募）
2 期
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of ObesityObesityNCT06565611Palatin Technologies, Inc108
招募中
2 期
Randomized Study Using SM-030 Gel for Adults With MelasmaMelasmaNCT06454747DermBiont, Inc.138